Oncolytic Herpes Simplex Virus 1 (HSV-1) vectors: Increasing treatment efficacy and range through strategic virus design Journal Article

   

Authors:	Carson, J.; Haddad, D.; Bressman, M.; Fong, Y.
Article Title:	Oncolytic Herpes Simplex Virus 1 (HSV-1) vectors: Increasing treatment efficacy and range through strategic virus design
Abstract:	Viruses have long been considered potential anticancer treatments. Wild-type viruses have been tested as anticancer agents in clinical trials since the 1960s. The possibility of viral oncolysis as an alternate cancer therapy was transformed by the emergence of modern genetic engineering. The herpes simplex virus (HSV) family offers particular advantages for use as a viral oncolytic. The engineered vectors that make up oncolytic HSVs (oHSVs) have demonstrated remarkable safety in clinical trials, with some evidence of efficacy. The past decade has seen a focus on increasing the efficacy of oncolytic vectors by adding exogenous transgenes to enhance tumor destruction. The current paper describes the various strategies for engineering HSV for increased cancer tissue specificity and efficacy. Presented are the rationale, preclinical data and clinical data where available. This is meant to illustrate a basic framework for the development of a novel therapy meant to exploit the viral life cycle for the killing of cancer. Copyright © 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
Keywords:	unclassified drug; gene deletion; clinical trial; review; squamous cell carcinoma; drug efficacy; drug safety; liver cell carcinoma; nonhuman; unspecified side effect; drug targeting; pancreas cancer; glioma; colorectal cancer; melanoma; protein targeting; lung non small cell cancer; drug design; cancer model; prostate cancer; colon cancer; oncolytic herpes virus; oncolytic virotherapy; liver cancer; brain cancer; cancer tissue; virus replication; herpes simplex virus 1; nv 1020; mouth cancer; cancer cell destruction; virus immunity; tissue specificity; g 207; nv 1034; g 47; g 47 delta; hsv 1716; nv 1042; nv 1066; oncovex; life cycle; virogenesis; virus entry; virus gene; virus inhibition; virus mutation; virus virulence; human
Journal Title:	Drugs of the Future
Volume:	35
Issue:	3
ISSN:	0377-8282
Publisher:	Prous Science
Date Published:	2010-01-01
Start Page:	183
End Page:	195
Language:	English
DOI:	10.1358/dof.2010.035.03.1470166
PROVIDER:	scopus
PMCID:	PMC3266817
PUBMED:	22287818
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84952989995&partnerID=40&md5=a46a45bd7b83b58740b24b0415e552aa
Notes:	Review -- Export Date: 3 February 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/87587